News
06-03-2008, 03:17 AM
Bavarian Nordic's subsidiary, BN ImmunoTherapeutics has initiated Phase I/II clinical studies with its therapeutic vaccine candidate against prostate cancer.
More... (http://www.news-medical.net/?id=38885)
More... (http://www.news-medical.net/?id=38885)